Enabling Clinical Programs Through Antibody Glycosylation, Upcoming Webinar Hosted by Xtalks
Summary
Patients with chronic autoimmune disease commonly present with the low circulating titers of sialylated antibodies, and therefore do not appropriately engage the Type II tolerizing Fc receptors. In this webinar, the experts will also provide some background on how glycosylation is linked to modulating the immune system and how the glycosylation pathways can be engineered for a range of drug development effects, including increasing half-life and bioavailability, enhancing antibody-drug conjugate (ADC) effects and modulating the anti-inflammatory response. Register for this webinar today to gain insights into the effects of glycosylation on drug efficacy and safety and how engineering glycan profiles can enhance clinical outcomes. Join Bjørn Voldborg, Head of the National Biologics Facility, Technical University of Denmark (DTU); Greg Coffey, PhD, Co-Founder & Vice President, Immunology & Clinical Translational Research, Nuvig Therapeutics; and Divya Teja Vavilala, PhD, Head of Protein Analytics, ATUM, for the live webinar on Monday, September 9, 2024, at 10am EDT (2pm BST/UK). Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities.